Navigation Links
Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program

DUBLIN, Calif., Sept. 17 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) has been awarded a $625,000 contract under the inaugural US Army Commercialization Pilot Program for the development of a Universal Sample Preparation Module (USPM). The Commercialization Pilot Program is a new program to assist SBIR firms that have Phase II projects that meet high priority Army requirements in transitioning to commercial products.

MBI's project will develop a Universal Sample Preparation Module that will automatically purify DNA from pathogen targets contained in complex matrices to provide samples for various downstream DoD-sponsored analytical platforms. The USPM will enable front-end sample preparation with high specificity for rapid detection, identification, and diagnosis of biological threat agents and will be applicable to detecting pathogens for molecular diagnostics. Using MBI's Microscale On-chip Valves (MOV(TM)) technology, the USPM will integrate multiple sample processing steps in a small, universal sample preparation module that integrates immunomagnetic separation capture with lysis and nucleic acid purification.

"Easy-to-use sample preparation, under field conditions, has always been a major obstacle to deploying back end pathogen detection and identification devices as well as molecular diagnostics devices. The USPM will greatly simplify this process and improve detection sensitivity," said Dr. Joanne Horn, Project Manager, heading the USPM development at MBI.

About Microchip Biotechnologies Inc.

Microchip Biotechnologies, Inc. (MBI) is developing the Apollo next-generation fluidics platform for Life Sciences, Applied Sciences, and Diagnostics markets. The Apollo platform incorporates MBI's proprietary BeadStorm(TM). bead-based sample preparation devices and patented "Microscale On-chip Valves" (MOV(TM)) valves, pumps, and routers on microchips to integrate, automate, and simplify workflows. The Company's first product, the Apollo 100, integrates advanced microfluidic sample preparation to reduce the cost of DNA sequencing. MBI is now adding analytical capabilities to Apollo platform to create breakthrough sample-to-answer devices for biodefense, DNA-based forensics and human identity (HID), and molecular diagnostics applications. MBI is privately held and based in Dublin, California; more details can be found on the Company's website:

SOURCE Microchip Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. Quick microchip test for dangerous antibiotic resistant bacteria
3. Team develops energy-efficient microchip
4. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
5. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
6. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
7. Melting defects could lead to smaller, more powerful microchips
8. MIT reports finer lines for microchips
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
11. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
Post Your Comments:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
Breaking Biology News(10 mins):